期刊文献+

非酒精性脂肪性肝病分子机制研究进展 被引量:1

Advances in Studies on Molecular Mechanisms of Nonalcoholic Fatty Liver Disease
暂未订购
导出
摘要 非酒精性脂肪性肝病(NAFLD)是一种以肝细胞脂肪变性和脂质沉积为特征,但无过量饮酒史的临床综合征.NAFLD疾病谱包括非酒精性单纯性脂肪肝、非酒精性脂肪性肝炎(NASH)、NASH相关肝纤维化和肝硬化.NAFLD的发病机制较为复杂,至今尚未完全阐明.本文就近年NAFLD分子机制研究的新进展,包括胰岛素抵抗(IR)、肝脂肪变性、氧化应激等方面作一综述. Nonalcoholic fatty liver disease (NAFLD) is a clinical syndrome characterized by hepatic steatosis and fat deposition in hepatocytes in the absence of significant alcohol use. NAFLD consists of a spectrum of disorders ranging from simple fatty liver, nonalcoholic steatohepatitis (NASH) and fibrosis/cirrhosis. The mechanism of NAFLD is complicated and has not been clarified yet. This article reviewed the new progress in the study of molecular mechanisms of NAFLD in recent years, including insulin resistance (IR), hepatic steatosis, and oxidative stress.
作者 王燕 陆伦根
出处 《胃肠病学》 2010年第4期246-248,共3页 Chinese Journal of Gastroenterology
关键词 非酒精性脂肪性肝病 胰岛素抗药性 氧化性应激 分子作用机制 Nonalcoholic Fatty Liver Disease Insulin Resistance Oxidative Stress Molecular Mechanisms of Action
  • 相关文献

参考文献1

二级参考文献92

  • 1[37]Gholam PM,Flancbaum L,Machan JT,Charney DA,Kotler DP.Nonalcoholic fatty liver disease in severely obese subjects.Am J Gastroenterol 2007; 102:399-408
  • 2[38]Hui JM,Kench JG,Chitturi S,Sud A,Farrell GC,Byth K,Hall P,Khan M,George J.Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.Hepatology 2003; 38:420-427
  • 3[39]Angelico F,Del Ben M,Conti R,Francioso S,Feole K,Fiorello S,Cavallo MG,Zalunardo B,Lirussi F,Alessandri C,Violi F.Insulin resistance,the metabolic syndrome,and nonalcoholic fatty liver disease.J Clin Endocrinol Metab 2005; 90:1578-1582
  • 4[40]Liangpunsakul S,Chalasani N.Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome:results from the third National Health and Nutrition Survey (NHANES Ⅲ).Am J Med Sci 2005; 329:111-116
  • 5[41]Nilssen O,Forde OH,Brenn T.The Tromso Study.Distribution and population determinants of gamma-glutamyltransferase.Am J Epidemiol 1990; 132:318-326
  • 6[42]Robinson D,Whitehead TP.Effect of body mass and other factors on serum liver enzyme levels in men attending for well population screening.Ann Clin Biochem 1989; 26:393-400
  • 7[43]Wannamethee G,Ebrahim S,Shaper AG.Gamma-glutamyltransferase:determinants and association with mortality from ischemic heart disease and all causes.Am J Epidemiol 1995; 142:699-708
  • 8[44]Perry IJ,Wannamethee SG,Shaper AG.Prospective study of serum gamma-glutamyltransferase and risk of NIDDM.Diabetes Care 1998; 21:732-737
  • 9[45]Yamada J,Tomiyama H,Yambe M,Koji Y,Motobe K,Shüna K,Yamamoto Y,Yamashina A.Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome.Atherosclerosis 2006; 189:198-205
  • 10[46]Stranges S,Trevisan M,Dorn JM,Dmochowski J,Donahue RP.Body fat distribution,liver enzymes,and risk of hypertension:evidence from the Western New York Study.Hypertension 2005; 46:1186-1193

共引文献59

同被引文献9

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部